CTLA4 and metastatic melanoma: In a study by Sade-Feldman, the authors analyzed longitudinal tumor biopsies from 17 metastatic melanoma patients and observed that B2M deficiency was more prevalent in non-responder patients (29.4%) compared to responders (10%) treated with anti-CTLA-4 or anti-PD-1 therapy.